CSIMarket Company Name, Ticker, Competitors, else..
 
Zyversa Therapeutics Inc   (ZVSA)
 
Price: $0.0990 $0.00 0.000%
Day's High: $0.0989999994635582 Week Perf: 0.00
Day's Low: $ 0.10 30 Day Perf: -1.98 %
Volume (M): 3 52 Wk High: $ 0.30
Volume (M$): $ 0 52 Wk Avg: $0.17
Open: $0.10 52 Wk Low: $0.08



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 8
 Employees 6
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -24
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Zyversa Therapeutics Inc is a biotechnology company that focuses on developing innovative therapies for patients with rare and serious inflammatory diseases. The company aims to address unmet medical needs and improve patient outcomes through the discovery and development of novel drug candidates. Zyversa Therapeutics utilizes advanced scientific techniques and technologies to identify potential treatments and conduct clinical trials for various inflammatory conditions. They are committed to advancing the field of biotechnology and improving the lives of patients suffering from debilitating diseases.


   Company Address: 2436 N. Federal Highway Lighthouse Point 33064 FL
   Company Phone Number: 231-1688   Stock Exchange / Ticker: ZVSA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        1.92% 
BMY   -4.2%    
JNJ   -2.74%    
LLY   -0.65%    
MRK   -3.31%    
PFE   -2.48%    
• View Complete Report
   



Clinical Study

ZyVersa Therapeutics Innovating Diabetes Management While Ensuring Financial Resilience,

Published Wed, Sep 10 2025 12:01 PM UTC

Balancing Innovation and Financial Stability: ZyVersa Therapeutics at the Forefront of Type 2 Diabetes and Cardiovascular Disease Management ZyVersa Therapeutics is emerging as a relevant player in the realm of type 2 diabetes mellitus (T2DM) management, leveraging innovative approaches aimed at the underlying mechanisms driving both diabetes and its common cardiovascular co...
Clinical Study

Targeting the NLRP3 Inflammasome A Dual-Action Strategy for Cardioprotection and Metabolic Correction in O...

Published Tue, Mar 11 2025 7:37 AM UTC

Exploring the Role of NLRP3 Inflammasome Inhibition in Obesity-Linked Heart Failure and Metabolic Disorders Obesity is a multifaceted chronic condition often associated with heart failure and metabolic dysregulation. The intersection of these comorbidities is complex, characterized by systemic inflammation, impaired heart function, and metabolic disturbances such as insulin ...
Clinical Study

Evaluating the Therapeutic Potential of ZyVersas IC 100 in Stroke-Related Cardiovascular Injury Amidst Mixed Market ...

Published Wed, Nov 20 2024 12:55 PM UTC

Recent research published by ZyVersa Therapeutics has outlined promising findings regarding their inflammasome ASC inhibitor, IC 100, in the context of stroke-related cardiovascular injury and dysfunction. This significant peer-reviewed study underscores the potential of IC 100 as a protective agent against cardiovascular complications associated with strokes, specifically b...
Clinical Study

Targeting Inflammasome Pathways in Obesity-Related Metabolic Dysfunction Insights from ZyVersa Therapeutics’ IC 100

Published Tue, Nov 5 2024 12:00 PM UTC

The rising prevalence of obesity and its associated metabolic complications poses a significant public health challenge globally. The underlying mechanisms contributing to the transition from obesity to insulin resistance and type 2 diabetes are complex and multifaceted, with recent research highlighting the pivotal role of inflammasome-driven inflammation. ZyVersa Therapeut...
Management Announcement

ZyVersa Therapeutics Charts Path Forward Amidst Financial Challenges with Promising Obesity Treatment

Published Thu, Oct 17 2024 11:50 AM UTC

In a recent letter to shareholders, Stephen C. Glover, CEO of ZyVersa Therapeutics, detailed the company’s ambitious plans for the next nine months centered around its investigational treatment, the Inflammasome ASC Inhibitor IC 100. Glover expressed optimism that this innovative therapy, aimed at mitigating chronic inflammation associated with obesity, could not only comb...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.02
Working Capital Ratio 0.05
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.35 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 0.04 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -4,081,472
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.